Carolina Landolt-Marticorena
University Health Network
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Carolina Landolt-Marticorena.
Nature Genetics | 2015
Leila Noetzli; Richard W. Lo; Alisa B. Lee-Sherick; Michael U. Callaghan; Patrizia Noris; Anna Savoia; Madhvi Rajpurkar; Kenneth L. Jones; Katherine Gowan; Carlo L. Balduini; Alessandro Pecci; Chiara Gnan; Daniela De Rocco; Michael Doubek; Ling Li; Lily Lu; Richard Leung; Carolina Landolt-Marticorena; Stephen P. Hunger; Paula G. Heller; Arthur Gutierrez-Hartmann; Liang Xiayuan; Fred G. Pluthero; Jesse W. Rowley; Andrew S. Weyrich; Walter H. A. Kahr; Christopher C. Porter; Jorge Di Paola
Some familial platelet disorders are associated with predisposition to leukemia, myelodysplastic syndrome (MDS) or dyserythropoietic anemia. We identified a family with autosomal dominant thrombocytopenia, high erythrocyte mean corpuscular volume (MCV) and two occurrences of B cell–precursor acute lymphoblastic leukemia (ALL). Whole-exome sequencing identified a heterozygous single-nucleotide change in ETV6 (ets variant 6), c.641C>T, encoding a p.Pro214Leu substitution in the central domain, segregating with thrombocytopenia and elevated MCV. A screen of 23 families with similar phenotypes identified 2 with ETV6 mutations. One family also had a mutation encoding p.Pro214Leu and one individual with ALL. The other family had a c.1252A>G transition producing a p.Arg418Gly substitution in the DNA-binding domain, with alternative splicing and exon skipping. Functional characterization of these mutations showed aberrant cellular localization of mutant and endogenous ETV6, decreased transcriptional repression and altered megakaryocyte maturation. Our findings underscore a key role for ETV6 in platelet formation and leukemia predisposition.
Annals of the Rheumatic Diseases | 2009
Carolina Landolt-Marticorena; G Bonventi; A Lubovich; C Ferguson; T Unnithan; J Su; Dafna D. Gladman; Murray B. Urowitz; Paul R. Fortin; Joan E. Wither
Objective: To study the longitudinal expression of interferon (IFN)-inducible genes in systemic lupus erythematosus (SLE) and determine their suitability as disease biomarkers. Methods: RNA was isolated from the peripheral blood of 94 patients with SLE and 11 controls and reverse transcribed into cDNA. The expression levels of five IFN-responsive genes (LY6E, OAS1, IFIT1, ISG15 and MX1) were determined by quantitative PCR, normalised to GAPDH and summed to generate a global IFN score. Patients were followed longitudinally for a period of 3–12 months, and the association between disease activity, as measured by the SLE disease activity index (SLEDAI-2K), and other clinical and laboratory variables was examined. Results: The expression of all five IFN-responsive genes was significantly higher in patients with SLE than in controls. The expression of LY6E, OAS1, IFIT1 and the global IFN score was associated with high disease activity. The global IFN score was also associated with active renal disease, a decreased C3, and the presence of anti-dsDNA or anti-RNA binding protein antibodies at a single point in time. However, there was a poor correlation between changes in this score and changes in disease activity, C3 or anti-dsDNA antibody levels in patients followed longitudinally. In most patients the levels of IFN-induced gene expression remained relatively stable over 3–12 months despite marked changes in disease activity. Nevertheless, in patients with low/moderate disease activity, those with high IFN scores had a more recent history of sustained high disease activity. Conclusion: The findings indicate that IFN-induced gene expression has limited clinical utility as a biomarker of acute changes in disease activity.
Blood | 2013
Walter H. A. Kahr; Richard W. Lo; Ling Li; Fred G. Pluthero; Hilary Christensen; Ran Ni; Nima Vaezzadeh; Cynthia Hawkins; Andrew S. Weyrich; Jorge Di Paola; Carolina Landolt-Marticorena; Peter L. Gross
Gray platelet syndrome (GPS) is an inherited bleeding disorder associated with macrothrombocytopenia and α-granule-deficient platelets. GPS has been linked to loss of function mutations in NEABL2 (neurobeachin-like 2), and we describe here a murine GPS model, the Nbeal2(-/-) mouse. As in GPS, Nbeal2(-/-) mice exhibit splenomegaly, macrothrombocytopenia, and a deficiency of platelet α-granules and their cargo, including von Willebrand factor (VWF), thrombospondin-1, and platelet factor 4. The platelet α-granule membrane protein P-selectin is expressed at 48% of wild-type levels and externalized upon platelet activation. The presence of P-selectin and normal levels of VPS33B and VPS16B in Nbeal2(-/-) platelets suggests that NBEAL2 acts independently of VPS33B/VPS16B at a later stage of α-granule biogenesis. Impaired Nbeal2(-/-) platelet function was shown by flow cytometry, platelet aggregometry, bleeding assays, and intravital imaging of laser-induced arterial thrombus formation. Microscopic analysis detected marked abnormalities in Nbeal2(-/-) bone marrow megakaryocytes, which when cultured showed delayed maturation, decreased survival, decreased ploidy, and developmental abnormalities, including abnormal extracellular distribution of VWF. Our results confirm that α-granule secretion plays a significant role in platelet function, and they also indicate that abnormal α-granule formation in Nbeal2(-/-) mice has deleterious effects on megakaryocyte survival, development, and platelet production.
The Journal of Rheumatology | 2011
Elaheh Aghdassi; Wendy Zhang; Yvan St-Pierre; Ann E. Clarke; Stacey Morrison; Valentina Peeva; Carolina Landolt-Marticorena; Jiandong Su; Heather N. Reich; James W. Scholey; Andrew M. Herzenberg; Janet E. Pope; Christine A. Peschken; Joan E. Wither; Paul R. Fortin
Objective. To compare the healthcare cost and loss of productivity in patients with systemic lupus erythematosus (SLE) with (LN) and without lupus nephritis (lupus nephritis-negative, LNN). Method. Patients were classified into those with active (ALN and ALNN) and inactive disease (ILN and ILNN). Patients reported on visits to healthcare professionals and use of diagnostic tests, medications, assistive devices, alternative treatments, hospital emergency visits, surgical procedures, and hospitalizations as well as loss of productivity in the 4 weeks preceding enrollment. Results. Enrollment was 141 patients, 79 with LN and 62 LNN. Patients with LN were more likely to visit rheumatologists and nephrologists, undergo diagnostic tests, and had higher costs for medications than patients who were LNN. The annual healthcare cost averaged
Journal of Biological Chemistry | 1999
Carolina Landolt-Marticorena; Walter H. A. Kahr; Paul Zawarinski; Judy Correa; Morris F. Manolson
CAN 12,597 ± 9946 for patients with LN and
The Journal of Rheumatology | 2011
Carolina Landolt-Marticorena; Robert Wither; Heather N. Reich; Andrew M. Herzenberg; James W. Scholey; Dafna D. Gladman; Murray B. Urowitz; Paul R. Fortin; Joan E. Wither
10,585 ± 13,149 for patients who were LNN, a difference of
Rheumatology | 2015
Timothy Li; Stephenie D. Prokopec; Stacey Morrison; Wendy Lou; Heather N. Reich; Dafna D. Gladman; Murray B. Urowitz; James W. Scholey; Paul R. Fortin; Paul C. Boutros; Joan E. Wither; Carolina Landolt-Marticorena
2012 (95% CI –
Journal of Autoimmunity | 2015
Nan-Hua Chang; Timothy T. Li; Julie J. Kim; Carolina Landolt-Marticorena; Paul R. Fortin; Dafna D. Gladman; Murray B. Urowitz; Joan E. Wither
2075,
Biochemistry and Cell Biology | 1998
Homa Kameh; Carolina Landolt-Marticorena; Jeffrey H. M. Charuk; Harry Schachter; Reinhart A. F. Reithmeier
6100). Patients with ALN had more diagnostic tests and surgical procedures, contributing to a significantly higher annual direct cost (
The Journal of Rheumatology | 2010
Lang-Jing Zhu; Carolina Landolt-Marticorena; Timothy T. Li; Xiao Yang; Xueqing Yu; Dafna D. Gladman; Murray B. Urowitz; Paul R. Fortin; Joan E. Wither
14,224 ± 10,265) compared to patients with ILN (